🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Ab#5015 ASCO #ASCO25 by Dr Andrew Parsonson 👉bit.ly/43DX82R👉Ph1/2 study of novel B7-H3-targeting ADC (DB 1311/BNT324) in CRPC #prostatecancer 👉Encouraging efficacy (unconfirmed ORR 27.9%) & manageable safety👇Mark Stein OncoAlert UroToday.com PCF Science

X-torial: Cleaning up the misinformation about Joe Biden and #ProstateCancer that I am reading everywhere. The purpose of this is to provide education from someone who treats and studies PCa for a living, lead the USA National Comprehensive Cancer Network (NCCN) PCa guidelines, hold leadership in NRG Oncology National Cancer Institute

Heartiest congratulations 🎉 to our stellar mentee Cindy Y. Jiang MD Anderson Cancer Center (co-mentored with #JJGao and Matt Campbell MD, MS) for being awarded the ASCO Conquer Cancer, the ASCO Foundation young investigator award on her research advancing our #MTAPloss story in #bladdercancer!

Stunning research from Edmond Kwan on ctDNA in theranostics: 🧬Low ctDNA predicts better response with ¹⁷⁷Lu-PSMA-617 vs. cabazitaxel chemotherapy ⚠️PTEN alterations linked to worse outcomes on cabazitaxel 🧪ATM defects tied to favorable PSMA-617 results 🩻PET quantitative

On the eve of #ASCO25, I am delighted to share results from the correlative analyses of the ANZUP phase II TheraP study, now published in Nature Medicine. Massive effort supported by dedicated co-investigators, coordinators, patients & families from 11 study sites across

🚨We’re hiring The Christie NHS! Great opportunity for a motivated clinician to join us as a Clinical Research Fellow in Urology! 🏥 Gain hands-on experience in tertiary surgical uro-oncology 🔬 Contribute to impactful research in prostate cancer ✍️ healthjobsuk.com/job/v7230918

Exciting to see initial results from step 1 of PDIGREE by Tian Zhang, MD, MHS lower CR rate than expected and a meaningful subset did not make it to step 2. This remains a study that we’ll all await the primary results from as it could impact practice #ASCO25

Deep, multi-omic analysis of adjuvant atezolizumab for ccRCC by Sumanta K. Pal, MD, FASCO and team building on prior KIM-1 studies. One take away is KIM-1 high, Teff high has longer DFS with atezo than placebo #ASCO25

With all the amazing presentations at #ASCO25, just wanted to take a moment to share some of our data related to #biomarkers from the #IMmotion010 phase III study, a trial of adjuvant #atezolizumab vs pbo. A tremendous team helped me put this together, including Wenxin (Vincent) Xu

Casdatifan + cabo 60 for 2L and 3L tx or metastatic ccRCC by Toni Choueiri, MD Phase 1 study shows ORR of 46% with median 5m fu (cabo mono is ~40-%). Phase 3 PEAK-1 coming soon

Phase 1 CART therapy in RCC (n=48). Treatment with ALLO-316 (anti-CD70). Quite significant tox as expected with CRS and autoimmune tox etc. RRs of 26% with short follow up in heavily pretreated patients. Cure/deep response should be the ambition #ASCO25

Pasritamig, an hK2 x CD3 bispecific, was remarkably tolerable with low rates of CRS and had encouraging activity in mCRPC in the phase 1 trial.

What are the latest approaches to prostate cancer treatment? Drs. Ana Aparicio and Andrew Hahn will be available to share insights on Monday, June 2 at 2:30 p.m. in #ASCO25 booth 10059. Learn more about prostate cancer treatment options offered at MD Anderson here:

😇I'm thrilled and humbled to receive the Next Gen Disruptor Award. Heartfelt thanks HemOnc Today Healio! ASCO #ASCO25 #HealioInnovators 🙏I'm deeply grateful for the incredible mentors, sponsors, collaborators and friends who opened doors and supported me along the way.

🔔Make sure to check our study!! ASCO #ASCO25 ⭐️#HighFiber (HF) #diet to modulate microbiome and outcomes in #immunotherapy in #Melanoma ✅ORR: ⬆️HF 77% Cntrl 29% ✅No significant GI related or Immune related AEs with HF diet ✅Cutaneous adverse events⬇️ w HF ✅ impressive EFS

Congrats Nick James also on @Prof-Nick-James.bsky.social & team👉@asco #ASCO25 👉a prognostic digital pathology based AI score (ArteraAI) identifies pts with clinically high-risk #prostatecancer (non metastatic) 👉likely to benefit most from adding abiraterone to SOC OncoAlert UroToday.com Prostate Cancer Foundation

📢 #ASCO25 | AMPLITUDE Ph. III | mCSPC HRR Altered: AMPLITUDE shows Nira + AAP vs AAP alone significantly improves rPFS and OS in HRR-altered mCSPC. Oral presentation by Dr. #GerrhardtAttard AttardLab et al. Full abstract → [shorturl.at/xOsvk]

Breaking news ASCO #ASCO25 👉 1st biomarker selected, positive ph3 trial in mHSPC #ProstateCancer 👉Abiraterone+ niraparib/PARPi significant improve rPFS (favorable OS trend) in HRR+ pts (⬆️benefit in BRCApts), NGS testing must inall AttardLab PCF Science UroToday.com OncoAlert

🔥New pub from the lab demonstrating that CREB-mediated cholesterol metabolism is a druggable cancer target downstream of #CAMKK2 in #CRPC. This work was led by the great Chenchu w/ big help from others including Wenyi Wang & Eberlin Lab. cell.com/cell-reports/f… 1/5

Just in Clinical Cancer Research 👉Congrats Chadi Hage Chehade Umang Swami & GU Cancer Research Program @HuntsmanCancer team👉Poor outcomes w/ SOC Rx in mHSPC #prostatecancer w/HRRm in 637 real-world US pts👇 Flatiron Health Foundation Medicine Ryon Graf, PhD 👉 need to add PARPi 👉free link: bit.ly/3TsOw9i OncoAlert UroToday.com